[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mental-illness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mental-illness":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,75,104,135,171,207,235,274,297],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100631343","phase-2-safety-and-efficacy-of-hb-1-for-post-traumatic-stress-disorder-100631343",false,"NCT07499440","Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder","Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Male or female aged 18 to 65 years old, inclusive, at the time of informed consent.\n* Meets DSM-V Criteria for PTSD.\n* Minimum CAPS-5 score of at least 26 (based on the optimal diagnostic correspondence in the definitive CAPS-5 psychometric validation study).\n* Clinically stable on current medication and\u002For therapy regimen for at least 2 months, as determined by Investigator.\n* Willing to remain on current doses of other psychiatric medications throughout the length of the trial.\n* Willing and able to safely stop any medications that are contraindicated to be taken together with HB-1, as determined by Investigator.\n* Fluent in English.\n* Willing to take HB-1.\n* Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.\n* Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or agree to commit to use acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study. Investigator shall use discretion and familiarity with subject's preferred and usual lifestyle to understand if reporting of abstinence may be trusted to achieve 100% effectiveness. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.\n* Female subjects who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening within 7 days of dosing with study treatment.\n\nExclusion Criteria:\n\n* Any ongoing concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.\n* Ongoing treatment with benzodiazepines (e.g. alprazolam, diazepam, clonazepam, lorazepam) or opiates (e.g., codeine, morphine) as assessed by clinical interview and urine toxicology testing.\n* Ongoing treatment with any medication that has a clinically significant drug-drug interaction with either telmisartan or verapamil, per the verapamil SR and telmisartan FDA labels and per standard drug interaction compendia. These include but are not limited to: Inhibitors or inducers of cytochrome P450 (CYP)3A4 (including certain β-hydroxy β-methylglutaryl-CoA \\[HMG-CoA\\] reductase inhibitors), Ivabradine, Antihypertensive Agents (including Beta Blockers), Antiarrhythmic Agents, Lithium, Carbamazepine, Rifampin, Phenobarbital, cyclosporin, theophylline, Inhalation Anesthetics, Neuromuscular Blocking Agents, Telithromycin, mTOR inhibitors as well as strong P-glycoprotein inhibitors (e.g., macrolides, ritonavir, itraconazole, ketoconazole, cyclosporin, ritonavir, and ivermectin).\n* Diagnosis of Severe Substance Use Disorder, Obsessive-Compulsive Disorder (OCD), Bipolar I, Bipolar II disorder, or Psychotic disorder (per SCID-V) or Borderline Personality Disorder (per Short-Bord).\n* Active suicidal ideation and behavior (Columbia-Suicide Severity Rating Scale \\[C-SSRS\\] score ≥ 4 at Screening, or who has made a serious suicide attempt in the last 3 months).\n* Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to: severe uncontrolled hypertension, hypotension (below 90\u002F60 mmHg); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).\n* Any clinically significant electrocardiogram (ECG) abnormalities at screening.\n* Inadequate hepatic function defined as total bilirubin \\> 1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\> 3 × the ULN range of each institution.\n* Inadequate renal function defined as serum creatinine \\> 1.5 × the ULN range of each institution and\u002For estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin.\n* Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.\n* Already on treatment with either telmisartan or verapamil or both.\n* Documented contraindication to taking telmisartan or verapamil: (eg, prior drug allergy, Duchenne's muscular dystrophy, myasthenia gravis).\n* Pregnant or breastfeeding.\n* Participation in another current clinical trial or prior trial within the last three months.\n* Urinalysis evidence of exposure to substances that may interfere with HB-1 testing (per investigator discretion).","ALL","18 Years","65 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).",[27,28],"PTSD","Mental Illness","RECRUITING","2026-06-03",{"date":32,"type":33},"2026-06-04","ACTUAL",{"date":35,"type":21},"2026-06",{"date":37,"type":21},"2027-10",{"name":39,"class":40},"HB BioTech, LLC","INDUSTRY",15,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100498904","harm-reduction-services-100498904","NCT05776316","Harm Reduction Services","Culturally Response Integrated Harm Reduction Services for Black and Latinx People Who Use Drugs","HRS","Inclusion Criteria:\n\n* at least 18 years of age\n* self-identified as misusing opioids +\u002F- other substances (stimulants) in the past 30 days, confirmed by interview using DSM-5 criteria\n* English or Spanish speaking\n* able to provide informed consent.\n\nExclusion Criteria:\n\n* inability to provide informed consent or participate in the study procedures as proposed in the consent\n* active suicidal or homicidal ideation or an unstable psychotic disorder (schizophrenia, schizoaffective disorder) or mood disorder (bipolar disorder, severe major depressive disorder)\n* an unwillingness to be randomized.\n* are prisoners",{"count":20,"type":21},[52],"NA","The purpose of this study is to assess whether an integrated harm reduction intervention (IHRI), compared to harm reduction (HR) services as usual, will improve harm reduction service utilization among Black and Latinx people who use drugs (PWUD).",[55,56,28],"Drug Use","Substance Abuse",[58,59,60,55,61,62,63],"Harm Reduction","Latinx\u002FHispanix","Black\u002FAfrican American","Cocaine","Opioids","Methamphetamines","2026-03-17",{"date":66,"type":33},"2026-03-19",{"date":68,"type":33},"2024-11-25",{"date":70,"type":21},"2028-03-28",{"name":72,"class":73},"NYU Langone Health","OTHER",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100623437","validation-of-french-phq-4-and-pc-ptsd-5-screening-scales-100623437","NCT07396623","Validation of French PHQ-4 and PC-PTSD-5 Screening Scales","Validation of the French Versions of the PHQ-4 Anxiety and Depression Scale and the PC-PTSD-5 Post-Traumatic Stress Disorder Screening Scale","DEPSYSTAGE","Inclusion Criteria:\n\n* Age ≥ 18 years,\n* Outpatient or hospitalized for any health-related reason,\n* Oral and written proficiency in French,\n* Patient informed and willing to participate in the study,\n* Patient with health insurance coverage\n\nExclusion Criteria:\n\n* Individuals under legal protection measures (guardianship, conservatorship, or legal supervision),\n* Other factors preventing obtaining non-opposition or conducting the research, such as: limited French proficiency, hearing impairment, or significant cognitive disorders",{"count":84,"type":21},90,"554 Days","OBSERVATIONAL","Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD).\n\nScreening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated.",[28],[90,91,92,93],"Post-Traumatic Stress Disorder","Depression","Anxiety","Screening tool","2026-02-02",{"date":96,"type":33},"2026-02-09",{"date":98,"type":33},"2026-01-26",{"date":100,"type":21},"2027-08-15",{"name":102,"class":73},"Assistance Publique - Hôpitaux de Paris",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":103},"100390638","successful-transitions-and-reintegration-tools-for-veterans-start-vets-100390638","NCT04366531","Successful Transitions and Reintegration Tools for Veterans (START-VETS)","Development of a Psycho-social Transition Program and Transition Assessment Tools for Veterans With Mental Illness and\u002For Substance Use Disorders Leaving Prison","START-VET","Inclusion Criteria:\n\n* Veteran with mental illness and\u002For substance use disorder released from prison within the past 36 months\n\nExclusion Criteria:\n\n* psychosis or cognitive impairment precluding active participation",true,{"count":114,"type":21},20,[52],"This study will develop prison reentry materials for Veterans leaving prison.",[118,28,119],"Substance Use Disorder","Recently Incarcerated",[121,122,123,124],"reentry","Mental illness","prison","substance use disorder","2025-09-22",{"date":127,"type":33},"2025-09-26",{"date":129,"type":33},"2020-08-03",{"date":131,"type":21},"2026-12-31",{"name":133,"class":134},"VA Office of Research and Development","FED",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":155,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":103},"100331881","genetic-counselling-in-the-prevention-of-mental-health-consequences-of-cannabis-use-100331881","NCT03601026","Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use","Interdisciplinary Approach to Maximize Adolescent Potential: Genetic Counselling Interventions to Reduce Negative Environmental Effects","IMAGINE","Inclusion Criteria:\n\n* Enrolment in the Families Overcoming Risks and Building Opportunities for Well-being (FORBOW) study.\n* Age between 12 and 21 years.\n* Knowledge of English sufficient to benefit from the intervention.\n* Capacity to provide informed consent at most recent FORBOW assessment.\n* Provision of consent to be contacted about future studies at most recent FORBOW assessment.\n\nExclusion Criteria:\n\n* A diagnosis of severe mental illness (psychotic disorder, bipolar disorder, severe\u002Frecurrent depression) at baseline\n* Autism or intellectual disability of a degree that interferes with assessment (IQ \\\u003C 70)","12 Years","21 Years",{"count":146,"type":21},120,[52],"Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is poor and available treatments have limited efficacy. Most risk factors for SMI are either unchangeable (e.g., genetics) or difficult to alter (e.g., low socio-economic status). In contrast, cannabis use is one specific risk factor that could be avoided. Certain individuals are more vulnerable to the harmful effects of cannabis. Genetic factors can help us identify these high-risk individuals. One in three individuals are carriers of a higher-risk genetic variant, and cannabis users with this genotype are at up to 7-fold increased risk of developing schizophrenia. In our study, genetic counselling will be provided to participants by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype. Participants will be counselled regarding their individualized risk of developing and of not developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if the participants accept the genetic test results). The investigators hypothesize that this intervention will reduce exposure to cannabis compared to the youth who are not offered the intervention.",[28,150,151,152,153,154],"Schizophrenia","Bipolar Disorder","Major Depressive Disorder","Cannabis Use","Psychosis",[156,157,158,159,160,161],"Severe mental illness","Developmental psychopathology","Trial-within-cohort","Genetic counselling","Cannabis use","Prevention","2025-05-13",{"date":164,"type":33},"2025-05-14",{"date":166,"type":33},"2019-11-01",{"date":168,"type":21},"2027-09-01",{"name":170,"class":73},"Nova Scotia Health Authority",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":192,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100540305","a-transdiagnostic-mentalization-based-intervention-for-parents-with-mental-disorders-100540305","NCT06315114","A Transdiagnostic Mentalization-based Intervention for Parents With Mental Disorders","A Transdiagnostic Mentalization-based Intervention (LIGHTHOUSE Parenting Program) Versus Care as Usual for Parents With Mental Disorders in Adult Mental Health Service: a Randomised Clinical Trial","LIGHTHOUSE","Inclusion Criteria exclusive to the Outpatient Clinic\n\n* Age \\>18 years\n* Seeking treatment for one of the following non-psychotic disorders according to ICD-10: obsessive-compulsive disorder and anxiety disorders (F40-42), posttraumatic stress disorder (DF43), personality disorders (F60-61), or one of the previous disorders and a drug-or alcohol related disorder (F10-19) (i.e. 'dual diagnosis disorder')\n\nInclusion Criteria exclusive to the trial:\n\n* Parent of at least one child aged 0-17 years of age at baseline\n* Fluent i.e., sufficient Danish language skills\n* Parent is living with child or is in regular contact (min. 5 days monthly)\n* Written informed consent\n\nExclusion Criteria exclusive to the Outpatient Clinic:\n\n* Possibility of a learning disability (IQ\\\u003C75)\n* A diagnosis of schizotypal personality disorder or antisocial personality disorder\n* Presence of a comorbid psychiatric disorder that requires specialist treatment elsewhere\n* Concurrent psychotherapeutic treatment outside the clinic\n\nExclusion Criteria exclusive to the trial:\n\n* Acute suicidal risk or state of crises\n* Lack of informed consent\n* Acute child endangerment\n* Participation in another parenting focused intervention simultaniously",{"count":180,"type":21},170,[52],"The aim of this randomised clinical trial is to evaluate the short and longterm effects of a transdiagnostic mentalization-based intervention (Lighthouse MBT Parenting Program) compared to care as usal (CAU) for parents with a mental disorder in adult mental health service.",[184,185,186,187,188,28,189,190,191],"Mental Disorder","Behavior Disorders","Diagnosis, Psychiatric","Diagnosis Dual","Severe Mental Disorder","Psychiatric Disorder","Psychiatric Disease","Psychiatric Illness",[193,194,195,196,161,197],"Mental disorder","Parent","Child","Preventive intervention","Intergenerational transmission","2025-05-09",{"date":164,"type":33},{"date":201,"type":33},"2024-03-11",{"date":203,"type":21},"2028-04-01",{"name":205,"class":73},"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital",2,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":206},"100359959","comparative-effectiveness-of-iimr-versus-cdsmp-100359959","NCT03966872","Comparative Effectiveness of IIMR Versus CDSMP","Comparative Effectiveness of Integrated Illness Management and Recovery Versus the Chronic Disease Self-Management Program","Inclusion Criteria:\n\n* Serious Mental Illness (diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or chronic depression with moderate impairment in functioning) receiving services at Centerstone(KY and TN)\n* Diagnosis of a chronic medical condition increasing risk of early mortality from cardiovascular or respiratory disease (e.g., diabetes, hyperlipidemia, hypertension, COPD, heart failure, tobacco dependence, obesity), and at least 1 ER visit or hospitalization within the past year or judgment by the treatment team of substantial need for illness self-management training.\n\nExclusion Criteria:\n\n* Consumers who do not speak English\n* Consumers with either no, or a well-controlled medical condition will not be included\n* Individuals residing in a nursing home or other institution\n* Evidence of significant cognitive impairment as indicated by a Mini Mental Status Examination score \\\u003C24, will be excluded\n\nEligibility for the COVID -related substudy is dependent on enrollment and participation in the parent project.",{"count":215,"type":21},600,[52],"The study will enroll 600 people with serious mental illness who receive services at Centerstone in KY or TN and will compare two different evidence-based self-management interventions: Integrated Illness Management and Recovery (I-IMR), a program developed by the study team at Dartmouth that trains people with serious mental illness on physical and mental health self-management, and the Stanford Chronic Disease Self-Management Program (CDSMP), a program largely focused on physical health self-management that has been used widely in the general population.",[28,219],"Chronic Disease",[221,222,223,224,225],"integrated health","mental health","illness management","cardiovascular disease","physical health","2025-04-09",{"date":228,"type":33},"2025-04-10",{"date":230,"type":33},"2019-09-02",{"date":232,"type":21},"2027-01",{"name":234,"class":73},"Dartmouth-Hitchcock Medical Center",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":255,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":206},"100576742","co-occurence-of-mental-illness-and-problematic-alcohol-use-an-internet-based-cognitive-behavior-therapy-intervention-100576742","NCT06789250","Co-occurence of Mental Illness and Problematic Alcohol Use: an Internet-based Cognitive Behavior Therapy Intervention","CoMiT","Inclusion Criteria:\n\n* Age ≥18 years\n* AUDIT ≥ 6 points for women and ≥ 8 points for men\n* Symptoms of depression, anxiety disorder and\u002For stress-related illness\n* Adequate ability to speak, read and write Swedish\n* Having access to the internet and a smartphone, computer or other device.\n\nExclusion Criteria:\n\n* Ongoing psychological treatment.\n* Ongoing medication for AUD\n* Recent changes (within the past three months) in psychiatric medication or planned changes during the treatment period. New medication prescribed during the study shall be reported but will not lead to exclusion\n* Severe psychiatric disorders based on a Mini-International Neuropsychiatric Interview (MINI) interview and reported medical history\n* Severe medical conditions that may impede participation in the study\n* Severe cognitive impairment\n* Current suicidality\n* Severe alcohol addiction where specialized treatment is more appropriate\n* Risk for severe alcohol withdrawal symptoms with a need for medical treatment. Participation is possible after completing alcohol withdrawal treatment within the ordinary health-care system, accessible to the Swedish population.\n* Substance use disorder, other than alcohol or nicotine, within the past six months.",{"count":243,"type":21},240,[52],"The goal of this clinical trial is to learn if internet-based cognitive behavior therapy (ICBT ) works to treat co-occurent of problematic alcohol use and mental illness including mild to moderate symptoms of either depression, anxiety, stress or disturbed sleep.\n\nThe main questions the study aims to answer are:\n\n* Does the ICBT program lower the self-rated suffering from mental illness?\n* Does the ICBT program lower the self-reported alcohol intake? Researchers will compare the ICBT program to the participants who are rancomized to a control grout that receives weekly attention from the research team, to see if the treatment works. In both groups, the participants will have the opportunity to ask for support from a therapist during the week days.\n\nParticipants are adults living in Sweden. They will:\n\n* Receive an ICBT program supported by a trained therapist. It consists of modules that the participants will work with on their computer for 10 weeks. Some modules will be compulsory and other optional for the participants.\n* Fill out forms to rate their mental illness and alcohol intake at the start and the end of the study as well as once every week during treatment.\n\nPrimary outcome measures are depression, anxiety and stress symptoms (measured with Depression Anxiety and Stress Scale 21 (DASS-21)) and alcohol intake measured with self-reported amounts. Other, secondary, outcome measures used will for example be about insomnia symptoms and disability assessment. Pre-treatment measurement, post-treatment measurement and 6-months and 12-months follow up is planned to be collected through an online survey.",[247,248,249,28,250,251,252,253,254],"Alcohol Drinking Related Problems","Alcohol Use Disorders","Depressive Disorders","Mental Stress","Mental and Behavioral Disorders","Sleep Problems","Stress Disorders","Anxiety Disorder\u002FAnxiety State",[256,91,92,257,258,259,260,261,122,262,263],"Internet intervention","Individually tailored","Transdiagnostic","Internet-based cognitive behavioral therapy (ICBT)","Stress","Sleeping disorders","Harmful alcohol use","Alcohol addiction","2025-02-21",{"date":266,"type":33},"2025-02-24",{"date":268,"type":33},"2025-01-05",{"date":270,"type":21},"2026-05",{"name":272,"class":273},"Linkoeping University","OTHER_GOV",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":112,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":287,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100560109","identifying-parents-in-child-welfare-services-who-need-mental-health-support-depression-and-anxiety-symptoms-100560109","NCT06572865","Identifying Parents in Child Welfare Services Who Need Mental Health Support: Depression and Anxiety Symptoms","Identifying Parents in Child Welfare Services Who Need Mental Health Support: Depression and Anxiety Symptoms and Associated Factors","Inclusion Criteria:\n\n* A parental role in relation to a child 0-17 years old (the participant does not be a guardian or biological parent, can also be, for example, a partner to a parent).\n* A child welfare report has been filed for the child or the parent has reached out to the CWS themselves.\n\nExclusion Criteria:\n\n* Not able to read questionnaire in any available language and interpreter not available at the social services.",{"count":282,"type":21},290,"The main aim of this study is to examine the occurrence of mental health symptoms among parents referred to the Swedish child welfare services for child maltreatment and other family related risks. Additionally, to examine any variables associated with parents' levels of depression and anxiety.\n\nParents will respond to questionnaires administered by social workers. The level of depression and anxiety will be descriptively and statistically compared to clinical and normative samples. Additionally, statistical analyses will examine variables associated with parents\\' mental health symptoms.",[28,91,92],[28,91,92,286],"Parenting","NOT_YET_RECRUITING","2024-09-16",{"date":290,"type":33},"2024-09-19",{"date":292,"type":21},"2024-09-30",{"date":294,"type":21},"2025-09-30",{"name":296,"class":73},"Karolinska Institutet",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":112,"sex":16,"minAge":17,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":314,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":103},"100430131","exploring-empathy-and-compassion-using-digital-narratives-100430131","NCT04881084","Exploring Empathy and Compassion Using Digital Narratives","Learning to Care: Exploring Empathy and Compassion Using Digital Narratives","Inclusion Criteria:\n\n* 18-35 years of age\n* Not currently admitted to a hospital\n\nExclusion Criteria:\n\n* Not in age range (18-35 years of age)\n* Currently admitted to a hospital\n* Attended the digital storytelling workshop and made a digital story used in the RCT","35 Years",{"count":306,"type":21},80,[52],"Stories of suffering and struggle are shared continuously through digital formats such as internet videos, news stories, social marketing, and fundraising campaigns. Digital stories are often created and shared to generate awareness about a problem, impart knowledge on contemporary issues, or promote compassion. The practice of sharing critical life events and insights provided by these experiences are valuable for tellers and the listeners alike for catharsis, healing, reconciliation, and connectiveness. Portrayals of mental suffering are a matter of cultural and social interest as new media products become available to the public. Studies published since the 1990s overwhelmingly conclude that formal media depictions are biased, promoting the stereotype that people who suffer emotionally are mentally ill, dangerous, violent, or insane. Various agencies, organizations, and corporations are actively working to provide alternative stories\u002Fnarratives to mainstream media by means of video testimonials in social marketing and fundraising campaigns and, ultimately, by taking advantage of the Internet. The impact of this work is under-researched. However, preliminary evaluations of social marketing campaigns report mixed results and raise questions about their effectiveness. As well, the first-person narrative prepared digitally and shared online is also providing alternative narratives to mainstream media stories. People are increasingly using digital videos to share their stories, viewing this as an opportunity to understand their emotions and thoughts, come to terms with disgrace around sensitive, personal issues and marginalization while providing hope and encouragement to others. This proposed study focuses on the process of creating digital narratives\u002Fstories, especially stories of mental and emotional suffering, and their impact in terms of inciting empathy, compassion, and good citizenship among viewers.",[310,28,311,312,313],"Mental Disorders, Severe","Stigma, Social","Compassion","Empathy",[315,316,317,318,319,320,28],"Digital Narratives","Digital Testimonials","Digital Stories","Social Marketing","Fundraising campaigns","Stigma","2024-07-25",{"date":323,"type":33},"2024-07-29",{"date":325,"type":33},"2024-04-01",{"date":327,"type":21},"2024-12-30",{"name":329,"class":73},"McGill University"]